Evotec SE/€EVT
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Evotec SE
Evotec SE is a biotechnology company specializing in drug discovery and development solutions across various therapeutic areas, including neuroscience, oncology, and metabolic diseases. The company provides integrated services and innovative research through its platforms, such as EVOequity and INDiGO, which accelerate drug candidates from discovery to commercialization. Founded in 1993, Evotec is headquartered in Hamburg, Germany, and operates worldwide with multiple research sites in Europe and the United States. Through strategic collaborations with pharmaceutical and academic institutions, Evotec enhances its research capabilities and expands its global reach, leveraging advanced technologies and a collaborative approach to drive innovation in drug development.
Ticker
€EVT
Sector
Health
Primary listing
XETRA
Employees
4,766
Headquarters
Website
Evotec SE Metrics
BasicAdvanced
€1.2B
-
-€1.17
1.09
-
Price and volume
Market cap
€1.2B
Beta
1.09
52-week high
€10.62
52-week low
€5.06
Average daily volume
509K
Financial strength
Current ratio
2.028
Quick ratio
1.749
Long term debt to equity
45.803
Total debt to equity
52.482
Interest coverage (TTM)
-7.04%
Profitability
EBITDA (TTM)
1.165
Gross margin (TTM)
13.62%
Net profit margin (TTM)
-26.26%
Operating margin (TTM)
-10.22%
Effective tax rate (TTM)
-5.04%
Revenue per employee (TTM)
€170,000
Management effectiveness
Return on assets (TTM)
-2.42%
Return on equity (TTM)
-20.51%
Valuation
Price to revenue (TTM)
1.496
Price to book
1.3
Price to tangible book (TTM)
1.97
Price to free cash flow (TTM)
-15.468
Free cash flow yield (TTM)
-6.46%
Free cash flow per share (TTM)
-0.43
Growth
Revenue change (TTM)
1.50%
Earnings per share change (TTM)
128.61%
3-year revenue growth (CAGR)
6.66%
10-year revenue growth (CAGR)
23.77%
3-year earnings per share growth (CAGR)
30.40%
10-year earnings per share growth (CAGR)
43.89%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evotec SE stock?
Evotec SE (EVT) has a market cap of €1.2B as of August 10, 2025.
What is the P/E ratio for Evotec SE stock?
The price to earnings (P/E) ratio for Evotec SE (EVT) stock is 0 as of August 10, 2025.
Does Evotec SE stock pay dividends?
No, Evotec SE (EVT) stock does not pay dividends to its shareholders as of August 10, 2025.
When is the next Evotec SE dividend payment date?
Evotec SE (EVT) stock does not pay dividends to its shareholders.
What is the beta indicator for Evotec SE?
Evotec SE (EVT) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.